Illumina, Inc. $ILMN Stock Position Increased by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 75.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,296 shares of the life sciences company’s stock after purchasing an additional 4,871 shares during the period. NorthCrest Asset Manangement LLC’s holdings in Illumina were worth $1,597,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Empowered Funds LLC increased its stake in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $621,000. SG Americas Securities LLC boosted its position in shares of Illumina by 408.7% during the second quarter. SG Americas Securities LLC now owns 6,933 shares of the life sciences company’s stock worth $661,000 after buying an additional 5,570 shares during the period. Ensign Peak Advisors Inc boosted its position in shares of Illumina by 3.7% during the second quarter. Ensign Peak Advisors Inc now owns 61,703 shares of the life sciences company’s stock worth $5,887,000 after buying an additional 2,228 shares during the period. Finally, Prudential PLC bought a new position in Illumina in the 2nd quarter worth approximately $590,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

NASDAQ ILMN opened at $123.79 on Tuesday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The firm has a market capitalization of $18.93 billion, a PE ratio of 22.71, a P/E/G ratio of 2.38 and a beta of 1.45. The company’s 50 day simple moving average is $130.48 and its 200 day simple moving average is $121.14. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 2.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Evercore set a $150.00 price target on Illumina in a research report on Friday, February 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. UBS Group reissued a “neutral” rating and set a $135.00 price target on shares of Illumina in a report on Friday, February 6th. Finally, Barclays lifted their price objective on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.